| Předmět: |
|
| Zdroj: |
Drug Week; 10/18/2024, p2765-2765, 1p |
| Abstrakt: |
A new report presents fresh data on genitourinary tract agents, specifically focusing on the drug fesoterodine. Fesoterodine is commonly used to treat an overactive bladder. The study investigated the effects of genetic variations in certain enzymes and transporters on the pharmacokinetics and safety of fesoterodine in healthy volunteers. The results showed that the activity of the CYP2D6 enzyme may play a more significant role than the CYP3A4 enzyme in the pharmacokinetics of fesoterodine. Additionally, genetic variants in the UGT family of genes were associated with variations in the exposure and clearance of the active metabolite of fesoterodine. Further studies are needed to confirm these findings. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
